Member Info for sadoldgit

You silly little fool.

Mainstream media.

Nothing more than propodanda!

Russian economy is growing fact!

The outright winner of this war will be Russia

The West has bern trying tk break Rusdia fince the fiwndall of the Berlin wall. Yes thry saud and we will not encroach 1 inch further East.

Yet you decide to trust whst the liars say.

Ukraine has lost. Damage limitation now.

Oh no your Cocaine crack head Zelensky trying to oncite world war 3. It aint going to happen sonny.

Putin has already been told what will happen if NATO troops put boots on ground or launch an attack on Russia.

End of the West. No ifs no buts..l rske it yoh are conversant with Dead Hand?

Once a point is teached which is already predetermined the outcome is imevitable as all human involvement is remove.

That is use if Nuclear weapons

Now tell what is the point of a detterent?

What better detterent is there?

With regards to post war and sanctions being released. It is a bargaining chip. Who is going to pay for the siezed Russian property msintenance bill. 20 million pound properties plus and billion pound yachts that cost over a million a month to maintain and dock. Russuans will want that paid

The West are not in the driving seat.

The West need to sit down and listen to Russia.

If they dont the war will end for all parties very unfavourably. In the first hour of a start of a nuclear stike 100 million plus dead as direct result. That is just the start. The tanks are daft e ough to think that they would only use around 60% of America . These are the same lot that said Putin is bluffing.

The war will end on Russias terms. Russia is not the enemy. Those that drove Russia into this war are. Owners of weapons manufactures mining companies the Globalist Elite ! Those that conntrol the likes if the CIA. MI6 and Mossad.

If Israel is so good why they spend hundreds of billons of pounds on an Iron curtain? Russia could destroy Israel with one unstoppable missile

Yes lsrael controls the US the Uk and bougjt detruction upon Germany.

Two countries Israel are fearful of and that us China and Russia.

Russia or China could put a dent in Israel, Nice big crater about 4 mile across and a mile deep.

Europe has no money to go to war with. Germany Industry collapsed. Germany survived with cheap energy from Russia. Now they no longer can.

Some industries slowly moving production to China, Siemens that are massive are one.

Win win win for the Brics countries.

Are EUA safe. In my opinion yes, but all risk not removed. l am a tad more heavily invested than l were a year ago so that indicates my confidence.

War ? l would put in an educated guess be done and dusted by October 26 if not before. Sokner or later they need sit around the table and lam of the firm belief Zelensky wont be there.

Regards

Agree Blockbuster.

In addition we have already identified compounds that can penetrate blood brain barrier.

What is required is the optimisation of one of our compounds that show promise.

Hence now we have AI to in effect shorten this optimisation timescale and prepare pre clinical with a selected candidate or candidates.

I would postulate that the potential financial upside is way more than 1802.

An RNS that in any shape or form that indicates we have a potential candidate advancing into preclinical should work a little magic on the share price.

Started the year with a little top up at 8.33.06.

No real reason just adding to a very low price to what we have in the pipeline.

Regards

Good morning PC1954.

I would hazard a guess Tim working on CNS molecules. The tweaking aspect of the promising compound in conjunction with AI. JR l would hazard a guess also involved.

Translational studies following candidates selection and final candidate.

Regards and Happy and prosperous New Year to you

DP64, thankyou for your enlightening post.

Could you provide us the information that you rely on implying Sareum signed a deal for 737.

Have you not made a blunder?

If you have, is this just one of many?

As far as l can remember the licensing deal was between the CRT and Pronai Therapeutics later to become Sierra Oncology.

NOTHING TO DO WITH SAREUM ALL TO DO WITH CRT!

In addition l canot recall TM stating there would be a deal within next half year.

Perhaps on addittion to supplying the RNS supporting your statement in the above you could kindly submit the RNS detailing the 'deal in next half year'.

Regards

If the Tussuans on the ftont line are so embarassingly effective, then why is the EU and the Uk planning to dpend 100's of billion on defence.

It is a war of attrittion and the Ukranians closely followed by the Russians are advancing slowly westwards.

Rsssia will not be dictated to by the West. It will end on Russias terms.

What the West going to do?

Put NATO in.

That the end of the world as we know it.

Bluffing?

The West incorrectly assumed the Russians were bluffing just before yheylaunced SMO.

Sanctions?

Russians are seizing like for like. Ask VW who cannot absorb loss if manufactuting facilty in Russia. 3.4 billon.

VW cannot afford to produce cars in Germamy as cost more to produce than they can sell them for.

Germany the indhstrial power jouse if Europe is broken. The Chancellor of Germany is an ex Blackrock executive.

Those that put sanctions on Russia will face seizures and high taxation.

Hungary not experiencing any problens with Russia.

Ungortunately the policians over here are all to keen to please their WEF masters.

With regards to EUA my belief war will finish by year end. The end to killing and life can get back to some normality.

Regards

Good morning and Happy New year to you DP64.

I dont see HNWI getting involved. A minority shareholder going in and kicking some butt.

No l cannot see that as ever going to happen here. Compounds and pipeline far more valuable than Val.

We are realistically looking at best in class for Tyk2 Jak inhibitor. The reasonings behind this have been explained by both Tim and John who are top notch in this field.

Beprocitinib predicted peak sales of 4 billion dollars a year by mid 30's yet discontinueed in Psoriasis. 1801 can fill that loss with room to spare.

On successful toxicology results utilising a suitable excipient results should be in line with phase 1a. By analysing current strategy ie start with compatable recipient for animals asap then this will progess phase 2 readiness.

At this moment in time it will become very marketable. Now before posters start going on about efficacy and we dont know. What we dont know dont matter. Efficacy is related to dose and dose limiting toxicities put the limit on maximum dosing. That should put, and lets face it nothing is 100% certain, impressive efficacy values in indications as shown in slides eg Psoriasis SLE and AD.

But the BoD need to deliver on this. No problems with Tim and John as scientists and not saleman.

Salesman bs but you cannot do as a scientist

Sitting at the helm is Stephen " form an orderly queue' Parker.

To state when asked when is the toxicology testing going to start? Then reply early in the New Year with an actual start at end of May just about sums him up. That is not acceptable!

However, enough from me but l would add DP that if you yourself are a HNWI then please feel free to go to Pampisford and kick some butt. If not it rather diminishes the intent of your post.

Regards and have a great day

A happy new year and prosperous 2026 to all.

Personally l do not see a problem with Tim and John. They are both scientists and with regards to compound design through to end of preclinical, have bern nigh flawless.

There was no explanation as to what went wrong with toxicology trial.

From the information we have been given it all points to a toxic excipient for animals that is fine in humans as reason for stopping. As in an excipient now planned that is only for use in this animal toxicology trial.

A question remains as to who was at fault here.

Gopd communications and double checking that all is ok. Ie that means what can go wrong.

Never assume anything.

Stephen Parker will have known what the problem is. That would have known earlier on and l would suggest communications would have been a tad electric between SP and the CRO.

That is last year.

This year they need focus on 737 finding on licence or deal of somesort. Should not be a problem surely as was it not SP who remarked form an orderly queue!

They may well have to accept a low up front offer here. 67% of something is better than 67 of nothing.

1801 is still a great cause for optimism. With regards safety and tolerability way above our most advanced competitor that has predicted world wide turnover peak of 3.5 to 4 billion dollars in the mid 2030,'s. Our safety profile from phase1a trials confirms that we will not suffer the same dose limiting adverse effects that resulted in Priovant (subsidary of Pfizer) discontinuing trials in Psoriasis. Successful toxicology trial results should propel maret cap tio 100 million plus.

Effectively all risk removed and suitable for long unrestricted long term use.

1802 advancements made and l take it that translational studies all completed. Further updates needed with regards to trialling and wgat is the proposed course if action here.

Will be in the shadow of the failled toxocology study l feel but happy to be proved wrong.

Sareum knew from early on a fault with recipient that is my belief l may be wrong.

CNS and BBB new compound. We have identified 1 very promising candidate which reqyires optimising. We have the added advantage of AI assistance in this.

Due to the nature of jak inhibitors we stand a good chance of success here. Take into account the likes of Baricitinib that is being trialled in these areas of urgent unmet need albeit now discontinued in some. It wont mdke the Black box warnings go away, we have the advantage here in that we are at design stage at a very opportune moment.

We should hear of updates on developments soon.

If the BoD ever read this please take note that you need to improve communications and double check that all requirements are met. 1801 CTA and toxicology failure do not indicate good inderstanfings between parties.

I will say again that l wish everyone here a happy new year and happy healthy and prosperous 2026. Yes that includes the BoD

Nothing wrong with having a moan CB.

It dont do any harm.

We can look forward and trust the BoD will get their finger out.

Regular updates required . Sticking to expected timelines. A bit if slippage ok but in effect we have lost a complete year.on 1801.

Dont dwell on the past l was once told concentrate on the future.

Regards and have a great Christmas. CB and all.

If the compounds are no good Potnak no one will buy. 1801 is good. Should not be restricted by dose limiting toxicities.

Personslly deep down l do care, as will increase share holder value considerably and provide treatments in areas of unmet need.

Your comment of not caring explains your behaviour. I believe.

One minute you project failure the next a 2 billion valuation. If you dont understand the intricacies of pharna compounds, the areas of unmet need competitors compounds then how can you with any degree of integrity assign a value.

Breprocitinib projected annual turnover of peak sales at 4.5 billion per annum by 2035. Fact!

Before we even start we are better in Psoriasis.

1802 need to here clarification of clinical trual readiness . CTA application but we would need funds up front or have a partner with deep pockets. Likewise with 737.

737 is a very compatable CHk1 inhibitor. Far superior safety profile yet similar efficacy to Prexa.

If you look at the timing of Acrivons licence for Prexasertib you will find this happened around 8 to 10 months after Sierra Oncology removed 737 from the shop window. It was a desire to obtain by Acrivon a CHK1 inhibitor.

Now GSK at this tine were in discussions with Sierra Oncology. There was a change of CEO at Sierra Oncology. Stephen Dilley took over and lo and behold GSK bought Sierra Oncology outright.

GSK stated they had achieved their main objective ie Momo for commercialisation.

What was their secondary objective? After considerable delay both promising inhibitors, checkpoint 1, and a Wee1 inhibitor were returned. But SO held on to them as long as possible to the extent they had to return them due to terms in the contract. For a whole year SO progress with 737 was indicated as final design stage. Nothing progressed They even robbed funding to pay for momo.

The very favourable report involving Triparna Sen on the micro environment of using a Pd 1 inhibitor, low dose Gemcitabine gave excellent results. Yes in mice where 10 out of 10 mice had tumour regression, 8 out 10 no detectabke tumour. Most of these no trace of tumour 60 days post treament cessation. Circa end 2019.

737 came out if shop window mid 2020.

One of the authors of this dissertation was also an advisor to GSK. John V Heymach.

GSK had recently purchased the Tesaro pipeline for 5.1 billion. GSK pushed commercialisation heavily and forced it into Europe as a treatment an area of urgent unmet need. (Ovarian cancer, (HGSOC)) Slight restrictions were placed on these inhibitors by the EU. Ie their equivalent to the MHRA.

Do you honestly think that GSK would want a competitor to take on a potentially better performing compound to the loss of revenue to their PD -1 inhibitor?

737 and the Wee 1 inhibitor shared similar fates.

Indeed it was postulated by Sierra oncology that 737 may have greater commercial value than Momo. Share holders up in arms of the 1.9.million sale. 737 at this time

Predictive text not help either as will change complete sentence.

Plus it thinks it learns.

If l type incorrectly the word 'good' and type goid it will come up with 'gold mining'

Need buy myself new Laptop. New Samsung phone is a nightmare.

Good morning PC1954.

Apologies for the spelling. No, l were not on the juice. ( l do have a nice 21 year old GlenAllachie to crack open later).

I am using my mobile phone. There was a cut on end of my thumb. So l catch wrong letters as a mistake. I did read through and thought l had corrected them. Clearly l had not! Had to decipher myself. Must make sure l read before pressing send.

Yes understand developments with CNS but 1802 is dragging its heels a tad l feel.

All looks ok otherwise and fully concur with the post by Potnak.

It would appear they, as in Sareum are in a similar mode as when experienced setback with MHRA and then went to Oz. The whole caboodle with trial applocation and trial completed by specialist company in good time. Dare l say a degree of urgency has set in.

In effect the toxicology study should be a matter of formality with an already proved safety profile in phase 1a. Yes phase 1a short duration but any downsides likely to cause problems in long term use l feel woild have been picked up.

Preclinical testing was carried out at doses exceeding 30 x therapeutic dose. No problems encountered.

Sareum juust need gather some momentum.

Regards

Zasocitinib us Tyk2 inhibitor and bring within the confines of TYK2 family should present hood safety profike.

Tje downside here is it is dingke inhibition and not dual inhibition meaning potentially inferior efficacy to Tyk2 Jak1 that inhibits Interferon gamma.

With regards to the Chinese Tyk2 Jak 1 that was trialled in Oz. Superior efficacy to Sotyktu.

Eonderful better PASI score and of course over the 12 weeks and not 16 weeks.

On limited data there was indications of increased levels of triglycerides in the blood. High leveks can increase the risk of heart attacjs ir strokes.

For Psoriasis patients not that exciting as Psoriasis requires long term trestment

The sticking point here is the laid back attitude of the BoD. Approaching three snd a half years and all we achieved is a CTA accepted in OZ toand s completed phase1a trial.

SP's remark of level of achuevement with SDC1801 results are misleading.. the phase 1a trial was completed July 24. A very long planned 4 month toxicogy trial that ended disaterously dut to exvipienttixuc to animals.

For those that are thinking of commenting ' we dont know thst for sure. Or it has not been released to us garbage.

Then take note that they are not going to be using the same excipient in new toxicology ttusl.and will.use pne to be used solely for the purpose of animal.testing which exibits no toxicity to aninals.

The biggesr problem with Sareum and tfey have a history if is failling to deliver on time.

A four month toxicology test will have taken over 18 months and tfat is taking into acviunt SP timelines adhered to.

Somebody needs their arse kicking for costly and serious delay in completing a toxicology study.

What we have l believe is the best out there.

No good having the best if you cannot deliver mikestones on time.

Regards

Hsppy Christmas to.all and that includes the BoD should they care to read this chat board.

Great to hear from you falkirkfreamer.

We all would like a little exrra cash for Christmas as with rising prices and fiscal drag.

Just a comment here with respect to comms.

I sincerely hope that the BoD have greater communications with regards to potential partners they state we are in communication with.

Plenty of confidence with regards to 1801.

Small tweaks in the excipient to maximise benefit of once daily dosing. Crossing the tees and dotting the eyes springs to mind.

Good comms essential. Make comms 3 way.

Effective and honest communication essential. Preferably face to face.

Dont want a mix up in the future wuth some poor bugger being treated for Psoriasis that has the excipient intended for animal toxicology studies only..

Any serious side effects? No.

Minor events.

Well for some unknown reason a statistically significant number of patients have devloped a wet nose and cannot pass a lampost or tree with out taking a piddle up it. Not life threatening of course but anxeity can be reduced by a pat on the head and a few dog boscuits

You have to laugh at times

Seriously and more to the point we are always appear to be missing out on the full story.

As shareholders that is not good as they have our investment. Not much we can do.

As a potential partner, they can wash their hands of it and seek suitable compounds elsewhere.

Furthermore large companies do not like missed timescales. Our progress in 3 years has been far from acceptable.

Regards and have a great Christmas.

yes nothing wrong with taking a few hundred pounds or maybe a few thousand pounds

very reminiscent of the crpto wprls wherethe whales to a large extent control the price.

most lo

ikely will see a large delayed trade or two at end of day here.

look at hemo up and down like a *****s drawers on no news.

aim is ripe for this of course.

found an old pension had forgotten about.

transfer value less than paid in. will take 4 weeks l am told by h&l to have cash transferred to sipp.

will put half here and the other half in another little gem .

on a different note.

chk1 definately not dead.

prexasertib chk1 2 intravenous inhibitor to enter phase 3 trials.

now thats a first.

interestingly to include ultra low doses of gemcitabine.

now correct me if l am wrong. it was posted here a while ago the advantages of our 737 over prexasertib.

similar efficacy with prexasertib but in an indication or two a tad less efficacious tha prex.

but of course where we shine, is far superior safety profile and the ability for incombo therapy.

prex is nowhere near compatable with incombo therapies as 737.

plus we can be taken orally.

fairly good news hot off the press.

https://finance.yahoo.com/news/acrivon-therapeutics-announce-clinical-ongoing-123000995.html?guccounter=1&guce_referrer=ahr0chm6ly93d3cuz29vz2xllmnvbs8&guce_referrer_sig=aqaaaamzqhlcdcqtqijrfoxt8am0kwdrtzik9jbvtj1jpqyh21gp5tnwe9slt6dcaweurvpty3gftstadgslooyumxtw5vxvb1onvicqtuuj4xwumdd_dylfhavkqiy1amdst36sgtvx1bvgcmmrvl8upuj3waqxktkaw3bmcptfyllo

regards

I have not posted in a while. Fed up with the negative sentiment of doom and gloom. Not wasting my time on here.

I am here till successful licence or buyout of company. Those that trade feel free to do so but beware of their up and down agenda. Not all, and l have nothing against many of thise tgat fo trade up and down

Could not make AGM due to personal issues. Would have been great to had a chat with JR with regards 1801

Looked in depth after listening to AGM podcast several times.

Mattyboy apologies for not getting back earlier.

The facts are there of course and of course need to be read and understood and implictions looked into.

An exipient for animal toxicology study only.

Interferon gamma inhibited by dual inhubition. Cannot be obtained by Tyk2 alone.

No detectable Jak 2 activity.

I would put an educated guess that the excipient used was same as phase 1a. Many excipients that are fit for humans are toxic to animsls. Xylitol an artifcial sweetner and filler is extremely toxic to dogs is one there exist others Seizures, liver failure and death can result.

I had posted a while back on excipients and toxicology but was riduculed and undermined snd the thread did not stay up long. In my opinion and also those knowledgeable eorking for CRO, this should have been part of toxicology description in contract and most certainly should have been picked up by a reputable CRO. Is this poor communications again?

Some were saying and one in particular that the compound is finished!

They panic not on what they do know but on what they dont know

Importance of interferon gamma inhibition is that it is prevalent in most if not all areas of high unmet need and of course for the investor commercislisation value.

No dectable Jak2 activity mereley relates to the absence of mutated Jak2 in laboratory testing.

All good here and indicates what little bit of Jak2 we have does not create mutated Jak2.

There is a great deal more of course.

The BoD

SP just about ok

JR top notch.

Who carried out the discussions and involved in the contract draft?

All.in all the future for 1801 looks extremely promising is my view.

Nice to see a rise today.

Good post with regards to 7t7 krone.

Both Merck and GSK have experienced problems with ovarian cancer. (There is a report on this Dec 24) The problem being resitance to cancer treatment, in effect the failure of Jemperli and Zejula to extend life expectancy. Oh dear!

As most of us know all defective P53 in cell cycle ovarian, especially HGSOC ( closer to 95%) cancer.

CHK1 territory! Whilst resistance to CHK1 inhibitors does eventilually develop it should potenuially increase life expectancy significantly.

Much work carried out resulting in report by T Senn in 2019.

As a light read indication with regards to CHk1 and resistence to PD-1. Copy and paste below and AI generated reply is ok read

pd 1 inhibitor and ovarian cancer resisitance to treatment overcome with SRA737.

Regards

It msy well.be that JR and SP sre looking at patent extension or indeed a new patent for 737.

But bare in mind here as to who owns the patents. Should a 3rd party coose to develop further in an area which is outside current patent protection. In combo especially chk1 PD-1 or Parpi with LDG. Not sure how protected we are with the SO patents. It is a a lengthy job to extend a current patent but maybe they can use similar route ie in the manufacturing of a compound with regards to crystallisation of a compound as was patented in 1801,1802.

I would also go as far as to suggest possibilities away from US and UK and look at places like India thst has good capabilities to generic drugs and hence possible combo.

May be problematic here as perhaps even patent expiry drugs may have patent protection discouraging in combo use.

Regards

"Evergreening" Strategies (Follow-on Patents): Companies can file for new, separate patents on incremental innovations related to the original drug, such as:

New formulations (e.g., sustained-release versions)

New uses or indications (e.g., a drug for one condition is found to treat another)

New combinations of drugs

New manufacturing processes or different crystal forms (polymorphs)

Several companies suffered with Peel Hunt that went through RF crucification. They not have Sareum interests

Much more goes wrong they will be playing the last post.

Good say to all!